1887

Abstract

With the recent development of single B-cell cloning techniques, an increasing number of human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing antibodies have been isolated since 2009. However, knowledge regarding HIV-1-specific B cells in vivo is limited. In this study, an HIV-1-specific B-cell line was established using healthy PBMC donors by the highly efficient Epstein–Barr virus transformation method to generate immortalized human naïve B-cell libraries. The enrichment of HIV-1 envelope-specific B cells was observed after four rounds of cell panning with the HIV-1 envelope glycoprotein. An HIV-1 envelope-specific stable B-cell line (LCL-P4) was generated. Although this cell line acquired a lymphoblastic phenotype, no expression was observed for activation-induced cytidine deaminase, an enzyme responsible for initiating somatic hypermutation and class switch recombination in B cells. This study describes a method that enables fast isolation of HIV-1-specific B cells, and this approach may extend to isolating other B-cell-specific antigens for further experiments.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000706
2017-04-13
2019-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/4/791.html?itemId=/content/journal/jgv/10.1099/jgv.0.000706&mimeType=html&fmt=ahah

References

  1. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7: e1001251 [CrossRef] [PubMed]
    [Google Scholar]
  2. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P et al. Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285– 289 [CrossRef] [PubMed]
    [Google Scholar]
  3. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329: 856– 861 [CrossRef] [PubMed]
    [Google Scholar]
  4. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014; 158: 989– 999 [CrossRef] [PubMed]
    [Google Scholar]
  5. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492: 118– 122 [CrossRef] [PubMed]
    [Google Scholar]
  6. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med 2016; 375: 2037– 2050 [CrossRef] [PubMed]
    [Google Scholar]
  7. West AP, Scharf L, Scheid JF, Klein F, Bjorkman PJ et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014; 156: 633– 648 [CrossRef] [PubMed]
    [Google Scholar]
  8. Hilleman MR. Overview of the needs and realities for developing new and improved vaccines in the 21st century. Intervirology 2002; 45: 199– 211 [CrossRef] [PubMed]
    [Google Scholar]
  9. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17: 1055– 1065 [CrossRef] [PubMed]
    [Google Scholar]
  10. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012; 37: 412– 425 [CrossRef] [PubMed]
    [Google Scholar]
  11. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467: 591– 595 [CrossRef] [PubMed]
    [Google Scholar]
  12. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012; 30: 423– 433 [CrossRef] [PubMed]
    [Google Scholar]
  13. Hoot S, Mcguire AT, Cohen KW, Strong RK, Hangartner L et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 2013; 9: e1003106 [Crossref]
    [Google Scholar]
  14. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340: 711– 716 [CrossRef] [PubMed]
    [Google Scholar]
  15. Yang Z, Li J, Liu Q, Yuan T, Zhang Y et al. Identification of non-HIV immunogens that bind to germline b12 predecessors and prime for elicitation of cross-clade neutralizing HIV-1 antibodies. PLoS One 2015; 10: e0126428 [CrossRef] [PubMed]
    [Google Scholar]
  16. Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK. Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011; 331: 1203– 1207 [CrossRef] [PubMed]
    [Google Scholar]
  17. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004; 10: 871– 875 [CrossRef] [PubMed]
    [Google Scholar]
  18. Rosén A, Gergely P, Jondal M, Klein G, Britton S. Polyclonal Ig production after Epstein–Barr virus infection of human lymphocytes in vitro. Nature 1977; 267: 52– 54 [CrossRef] [PubMed]
    [Google Scholar]
  19. Liu YJ, Arpin C. Germinal center development. Immunol Rev 1997; 156: 111– 126 [CrossRef] [PubMed]
    [Google Scholar]
  20. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102: 553– 563 [CrossRef] [PubMed]
    [Google Scholar]
  21. Yu X, Tsibane T, Mcgraw PA, House FS, Keefer CJ et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455: 532– 536 [CrossRef] [PubMed]
    [Google Scholar]
  22. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5: e8805 [CrossRef] [PubMed]
    [Google Scholar]
  23. Yuan T, Li J, Zhang MY. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins. MAbs 2011; 3: 402– 407 [CrossRef] [PubMed]
    [Google Scholar]
  24. Sun Z, Li J, Hu X, Shao Y, Zhang MY. Reconstitution and characterization of antibody repertoires of HIV-1-infected “elite neutralizers”. Antiviral Res 2015; 118: 1– 9 [CrossRef] [PubMed]
    [Google Scholar]
  25. Dorner M, Zucol F, Berger C, Byland R, Melroe GT et al. Distinct ex vivo susceptibility of B-cell subsets to epstein–barr virus infection according to differentiation status and tissue origin. J Virol 2008; 82: 4400– 4412 [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000706
Loading
/content/journal/jgv/10.1099/jgv.0.000706
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error